Cilengitide

ArtNr	HY-16141-100mg
Hersteller	MedChem Express
CAS-Nr.	188968-51-6
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Skin Cancer
Typ	Inhibitors
Specific against	other
Purity	99.80
Citations	[1]Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrinreceptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7.\|[2]Kapp TG, et al. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Sci Rep. 2017 Jan 11;7:39805. \|[3]Pan X, et al. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered. 2022 Feb;13(2):4557-4572. Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427.\|Atherosclerosis Plus. 19 October 2022.\|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 31:167484.\|Bioengineered. 2022 Feb;13(2):4557-4572.\|Biomed Res Int. 30 Nov 2021.\|bioRxiv. 2020 Apr.\|bioRxiv. 2024 Aug 28:2024.08.27.609975.\|Blood Rev. 2022 Dec.\|Br J Cancer. 2023 Jan 30.\|Cancer Cell. 2021 Sep 28;S1535-6108(21)00492-X.\|Cancer Med. 2018 Feb;7(2):408-419. \|Cancers (Basel). 2023 Mar 12.\|Cell Biol Int. 2020 Apr;44(4):966-974.\|Cell Death Dis. 2022 Dec 7;13(12):1028.\|Cell Rep Med. 2025 Jan 16:101922.\|Cell Rep. 2022 Sep 27;40(13):111422.\|Cell Adh Migr. 2019 Jan 21:1-12. \|Cell. 2020 Aug 6;182(3):545-562.e23. \|Clin Transl Med. 2021 Oct;11(10):e548.\|Commun Biol. 2024 Dec 30;7(1):1713.\|Department of Bioengineering. Santa Clara University. Jun 12, 2014 .\|Engineering. 8 October 2020.\|Environ Pollut. 2023 May 12;121817.\|FASEB J. 2023 Feb;37(2):e22726.\|Free Radic Biol Med. 2024 Dec 9:227:296-311.\|Front Immunol. 2018 Jun 1;9:1207. \|Front Pharmacol. 2021 Feb 24;12:585778.\|Int Immunopharmacol. 2024 Jul 1:138:112545.\|J Cell Biol. 2023 Aug 7;222(8):e202303107.\|J Cell Physiol. 2024 Apr 1.\|J Chem Inf Model. 2023 Oct 3.\|J Immunother Cancer. 2020 Mar;8(1):e000111. \|J Integr Neurosci. 2024 Jul 25;23(7):140.\|J Mol Histol. 2020 Apr;51(2):147-159.\|J Transl Med. 2018 Dec 12;16(1):352.\|Lung. 2020 Dec;198(6):947-955.\|Mol Cancer Ther. 2022 Jul 6;mct.22.0093.\|Nat Cell Biol. 2020 Mar;22(3):289-296. \|Obesity. 2015 Apr;23(4):779-85. \|Patent. US20180263995A1.\|Patent. US20220378739A1.\|PLoS One. 2014 Oct 13;9(10):e110453.\|PLoS One. 2016 Feb 3;11(2):e0148333. \|Research Square Preprint. 2022 Jan.\|Scand Cardiovasc J. 2021 Jul 23;1-10.\|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.\|Biochem Pharmacol. 2025 Mar 12:116870.
Smiles	O=C(NCC(N[C@H](C(N[C@H](CC1=CC=CC=C1)C(N([C@H]2C(C)C)C)=O)=O)CC(O)=O)=O)[C@H](CCCNC(N)=N)NC2=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	EMD 121974
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Autophagy; Integrin; PD-1/PD-L1; STAT
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	588.66
Product Description	Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 44 mg/mL\|H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Cytoskeleton; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Isoform	STAT3; α5β1; αvβ3; αvβ5
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-16141-100mg-safety-datasheet.pdf